Drugs / LB2102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05680922 | Jul 2023 → Dec 2027 expected | pulmonary large cell neuroendocrine carcinoma, small cell lung carcinoma | Legend Biotech USA Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Nanjing Legend Biotech Co. | Results Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026 legendbiotech.com ↗
At higher dose levels, an objective response rate (ORR) of 28.6% and disease control rate (DCR) of 78.6% were observed, including durable responses in some heavily pretreated patients. |
| 2026-05-21 | Nanjing Legend Biotech Co. | Results Legend Biotech Announces Presentations at ASCO 2026 legendbiotech.com ↗
The rapid oral presentation for LB2102 underscores continued progress in extending CAR-T approaches into solid tumors, with preliminary data demonstrating a manageable safety profile and early evidence of clinical activity. |
| 2025-06-03 | Nanjing Legend Biotech Co. | Results Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting legendbiotech.com ↗
Promising early results from ongoing Phase 1 dose-escalation studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers underscore potential of next-generation cell therapies |
| 2025-05-22 | Nanjing Legend Biotech Co. | Results Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT legendbiotech.com ↗
Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors, specifically lung and gastric cancers respectively, will also be featured in poster presentations at ASCO. |
| 2022-11-21 | Nanjing Legend Biotech Co. | Regulatory Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer legendbiotech.com ↗
Legend Biotech Corporation (NASDAQ: LEGN) ( Legend Biotech ), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s Investigational New Drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adult patients with extensive stage small cell lung cancer (SCLC). |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Nanjing Legend Biotech Co. | Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026 legendbiotech.com ↗ |
| 2026-05-21 | Nanjing Legend Biotech Co. | Legend Biotech Announces Presentations at ASCO 2026 legendbiotech.com ↗ |
| 2025-06-03 | Nanjing Legend Biotech Co. | Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting legendbiotech.com ↗ |
| 2025-05-22 | Nanjing Legend Biotech Co. | Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT legendbiotech.com ↗ |
| 2022-11-21 | Nanjing Legend Biotech Co. | Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer legendbiotech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB2102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05680922 ↗ |
| Modality | Cell therapy | “DLL3 directed autologous Chimeric Antigen Receptor T-cells” NCT05680922 ↗ |